MedTrace Logo

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

NCT02442466 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-05-20

No results posted yet for this study

Summary

Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.

Conditions

Interventions

DRUG

Endothelin Receptor B inhibitor BQ788

DRUG

PBS

Sponsors & Collaborators

  • California Institute of Technology

    collaborator OTHER

  • University of Bern

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • MelCure SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442466 on ClinicalTrials.gov